Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections

References

• VergidisPIFalagasMEShimadaJYamaguchiKShibaTMultidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment optionsCurr Opin Investig Drugs200892176183
   PubMed Web of Science ®Google Scholar
• FritscheTRStilwellMGJonesRNAntimicrobial activity of doripenem (S-4661): a global surveillance report (2003)Clin Microbiol Infect2005111297498416307551
   PubMed Web of Science ®Google Scholar
• ShimadaJYamaguchiKShibaT[A new carbapenem antibiotic for injection: characteristics of doripenem]Jpn J Antibiot200558648950616521342
   PubMedGoogle Scholar
• PoulakouGGiamarellouHDoripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogensExpert Opin Investig Drugs2008175749771
   PubMed Web of Science ®Google Scholar
• LoTSWelchJMAlontoAMVicaldo-AlontoEAA review of the carbapenems in clinical use and clinical trialsRecent Pat Antiinfect Drug Discov20083212313118673125
   PubMedGoogle Scholar
• IkawaKMorikawaNUeharaSPharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patientsInt J Antimicrob Agents200933327627919095418
   PubMed Web of Science ®Google Scholar
• WeigeltJAEmpiric treatment options in the management of complicated intra-abdominal infectionsCleve Clin J Med200774Suppl 4S29S3717847176
   PubMedGoogle Scholar
• FukasawaMSumitaYHarabeETStability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase IAntimicrob Agents Chemother1992367157715791510457
   PubMed Web of Science ®Google Scholar
• ZhanelGGWiebeRDilayLComparative review of the carbapenemsDrugs20076771027105217488146
   PubMed Web of Science ®Google Scholar
• Package insert. Doribax® (doripenem for injection)Raritan, NJOrtho-McNeil Pharmaceuticals, Inc2008 Available from www.doribax.com/doribax/shared/pi/doribax.pdf Accessed: January 1, 2009.
   Google Scholar
• HagermanJKKnechtelSAKlepserMEDoripenem: A new extended-spectrum carbapenem antibioticFormulary200742676688
   Google Scholar
• NicolauDPCarbapenems: a potent class of antibioticsExpert Opin Pharmacother200891233718076336
   PubMed Web of Science ®Google Scholar
• GreerNDDoripenem (Doribax): the newest addition to the carbapenemsProc (Bayl Univ Med Cent)200821333734118628935
   PubMedGoogle Scholar
• Bulletin. New Product, Doribax® (Doripenem for Injection)Washington, DCAmerican Pharmacists Association2008
   Google Scholar
• MatthewsSJLancasterJWDoripenem monohydrate, a broad-spectrum carbapenem antibioticClin Ther2009311426319243706
   PubMed Web of Science ®Google Scholar
• KotapatiSNicolauDPNightingaleCHKutiJLClinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic conceptsAm J Health Syst Pharm200461121264127015259757
   PubMed Web of Science ®Google Scholar
• KatsubeTYanoYYamanoYPharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic modelJ Pharm Sci20089794108411718314887
   PubMed Web of Science ®Google Scholar
• KeamSJDoripenem: a review of its use in the treatment of bacterial infectionsDrugs200868142021205718778123
   PubMed Web of Science ®Google Scholar
• JonesRNHuynhHKBiedenbachDJActivities of doripenem (S-4661) against drug-resistant clinical pathogensAntimicrob Agents Chemother20044883136314015273134
   PubMed Web of Science ®Google Scholar
• CadaDLevienTMistryBBakerDDoripenem for InjectionHospital Pharmacy2008432210218
   Google Scholar
• NishioHKomatsuMShibataNMetallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of JapanJ Clin Microbiol200442115256526315528723
   PubMed Web of Science ®Google Scholar
• JonesRNSaderHSFritscheTRComparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanismsDiagn Microbiol Infect Dis2005521717415878447
   PubMed Web of Science ®Google Scholar
• SchwaberMJCarmeliYCarbapenem-resistant Enterobacteriaceae: a potential threatJAMA2008300242911291319109119
   PubMed Web of Science ®Google Scholar
• MushtaqSGeYLivermoreDMComparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamasesAntimicrob Agents Chemother20044841313131915047535
   PubMed Web of Science ®Google Scholar
• LiXZNikaidoHEfflux-mediated drug resistance in bacteriaDrugs200464215920414717618
   PubMed Web of Science ®Google Scholar
• MushtaqSGeYLivermoreDMDoripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potentialAntimicrob Agents Chemother20044883086309215273124
   PubMed Web of Science ®Google Scholar
• JonesRNSaderHSFritscheTRJanechekMJSelection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemDiagn Microbiol Infect Dis200759446747217997070
   PubMed Web of Science ®Google Scholar
• PRNewswire. “FDA requires additional information on Doribax for treatment of hospital-acquired pneumonia”. Johnson & Johnson Pharmaceuticals Research and Development L.L.C.; August 21, 2008 Available at: www.drugs.com/nda/fda-requires-additional-doribax-hospital-acquired-pneumonia-1610.html Accessed: January 14, 2009.
   Google Scholar
• LucastiCJasovichAUmehOEfficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority studyClin Ther200830586888318555934
   PubMed Web of Science ®Google Scholar
• MalafaiaOUmehOJiangJDoripenem versus meropenem for the treatment of complicated intra-abdominal infections [Abstract No L-1564b plus poster]47th Interscience Conference on Antimicrobial Agents and Chemotherapy2006San Francisco, CA, USA2006
   Google Scholar
• NaberKRedmanRKoteyPLlorensLKanigaKIntravenous therapy with doripenem versus Levofloxacin with an option for oral step down therapy in the treatment of complicated urinary tract infections and pyelonephritis [Abstract No. 833 plus poster]Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy2007 March 31–April 3Munich, Germany2007
   Google Scholar
• KamidonoSArakawaSHiroseTDouble-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection [in Japanese]Jpn J Chemother200553Suppl 1244259
   Google Scholar
• Rea-NetoANiedermanMLoboSMEfficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter studyCurr Med Res Opin20082472113212618549664
   PubMed Web of Science ®Google Scholar
• ChastreJWunderinkRProkocimerPEfficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized studyCrit Care Med20083641089109618379232
   PubMed Web of Science ®Google Scholar
• PsathasPAKuzmissionAIkedaKYasuoSStability of doripenem in vitro in representative infusion solutions and infusion bagsClin Ther200830112075208719108795
   PubMed Web of Science ®Google Scholar
• SaitoAWatanabeANakataKComparative study of doripenem and meropenem in respiratory infections. Phase III double-blind comparative study [in Japanese]Jpn J Chemother200553Suppl. 1185204
   Google Scholar
• ListerPDCarbapenems in the USA: focus on doripenemExpert Rev Anti Infect Ther20075579380917914914
   PubMed Web of Science ®Google Scholar
• HoriuchiMKimuraMTokumuraMAbsence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibioticsToxicology20062221–211412416549226
   PubMed Web of Science ®Google Scholar
• PrescottWAJrKusmierskiKAClinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergyPharmacotherapy200727113714217192167
   PubMed Web of Science ®Google Scholar
• MerchantSGastCNathwaniDHospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumoniaClin Ther200830471773318498921
   PubMed Web of Science ®Google Scholar
• KutiJLMaglioDNightingaleCHNicolauDPEconomic benefit of a meropenem dosage strategy based on pharmacodynamic conceptsAm J Health Syst Pharm200360656556812659058
   PubMed Web of Science ®Google Scholar
• Van WartSAAndesDRAmbrosePGBhavnaniSMPharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patientsDiagn Microbiol Infect Dis200963440941419249182
   PubMed Web of Science ®Google Scholar
• AndersonDLDoripenemDrugs Today (Barc)200642639940416845443
   PubMed Web of Science ®Google Scholar
• VollesDFBrananTNAntibiotics in the intensive care unit: focus on agents for resistant pathogensEmerg Med Clin North Am200826381383418655946
   PubMed Web of Science ®Google Scholar